Cargando…
Should We Use Clinical Tools to Identify Disease Progression?
The presence of disability progression in multiple sclerosis (MS) is an important hallmark for MS patients in the course of their disease. The transition from relapsing remitting (RRMS) to secondary progressive forms of the disease (SPMS) represents a significant change in their quality of life and...
Autores principales: | Inojosa, Hernan, Proschmann, Undine, Akgün, Katja, Ziemssen, Tjalf |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7859270/ https://www.ncbi.nlm.nih.gov/pubmed/33551982 http://dx.doi.org/10.3389/fneur.2020.628542 |
Ejemplares similares
-
Natalizumab Pharmacokinetics and -Dynamics and Serum Neurofilament in Patients With Multiple Sclerosis
por: Proschmann, Undine, et al.
Publicado: (2021) -
Influence of exercise on quantity and deformability of immune cells in multiple sclerosis
por: Proschmann, Undine, et al.
Publicado: (2023) -
The need for a strategic therapeutic approach: multiple
sclerosis in check
por: Inojosa, Hernan, et al.
Publicado: (2022) -
Drug and Neurofilament Levels in Serum and Breastmilk of Women With Multiple Sclerosis Exposed to Natalizumab During Pregnancy and Lactation
por: Proschmann, Undine, et al.
Publicado: (2021) -
Real-World Lab Data in Natalizumab Treated Multiple Sclerosis Patients Up to 6 Years Long-Term Follow Up
por: Kaufmann, Maxi, et al.
Publicado: (2018)